2000/77/EC: Commission Decision of 17 December 1999 for the purchase by the Community of foot-and-mouth disease antigens and for the formulation, production, bottling and distribution of vaccines against foot-and-mouth disease (notified under document number C(1999) 4683)
1. The Community shall purchase as soon as possible the following strains of foot-and-mouth disease antigen:
- A Iran 96: 1000000 doses,
- A Iran 99: 1000000 doses,
- A Malaysia 97: 500000 doses,
- SAT1: 500000 doses,
- SAT2 (Southern Africa): 500000 doses,
- SAT2 (East Africa): 500000 doses,
- SAT3: 500000 doses.
2. The Community shall make arrangements for formulation, production, bottling and distribution of vaccines against foot-and-mouth disease produced from antigens referred to in paragraph 1.
3. The maximum cost of the measures referred to in paragraphs 1 and 2 shall be up to EUR 2,5 million.
4. The action referred to in paragraph 3 shall be organised by the Commission before 31 December 1999.
The measures mentioned in Article 1(3) shall be carried out by the Commission in cooperation with the supplier designated by call for tender.
1. To meet the objectives of Articles 1 and 2 the Commission shall conclude contracts without delay.
2. The Director-General of the Directorate-General for Health and Consumer Protection shall be authorised to sign the contracts on behalf of the European Commission.
This Decision is addressed to the Member States.
Done at Brussels, 17 December 1999.
For the Commission
David BYRNE
Member of the Commission
(1) OJ L 224, 18.8.1990, p. 19.
(2) OJ L 160, 26.6.1999, p. 103.
(3) OJ L 368, 31.12.1991, p. 21.
(4) OJ L 301, 24.11.1999, p. 6.
(5) OJ L 280, 13.11.1993, p. 33.
(6) OJ L 269, 11.11.1995, p. 29.
(7) OJ L 148, 6.6.1997, p. 27.
Source: EUR-Lex (Publications Office of the EU), Β© European Union, reuse permitted under Commission Decision 2011/833/EU.
